TherapeuticsMD Announces Pricing of Public Offering of Common Stock
BOCA RATON, Fla. -- March 15, 2013
TherapeuticsMD, Inc. (OTCQB:TXMD) today announced the pricing of its
previously announced underwritten public offering of 29,411,765 shares of its
common stock, offered at a price of $1.70 per share to the public. The gross
proceeds to TherapeuticsMD from this offering are expected to be approximately
$50.0 million, before deducting underwriting discounts, commissions, and other
estimated offering expenses payable by TherapeuticsMD. All of the shares in
the offering are to be sold by TherapeuticsMD. The offering is expected to
close on or about March 20, 2013, subject to the satisfaction of customary
closing conditions. TherapeuticsMD has granted the underwriters a 30-day
option to purchase up to an aggregate of 4,411,765 additional shares of common
stock to cover over-allotments, if any.
Jefferies LLC acted as sole book-running manager for the offering, and Noble
Financial Capital Markets acted as co-manager.
A shelf registration statement on Form S-3 relating to the public offering of
the shares of common stock described above was filed with the Securities and
Exchange Commission ("SEC") and has been declared effective by the SEC. A
preliminary prospectus supplement relating to the offering has been filed with
the SEC and a final prospectus supplement relating to the offering will be
filed with the SEC and will be available on the SEC's web site at www.sec.gov.
When available, copies of the final prospectus supplement may also be obtained
from the offices of Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by telephone
at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
TherapeuticsMD, Inc. is a women’s healthcare product company focused on
creating and commercializing products targeted exclusively for women. The
Company currently manufactures and distributes branded and generic
prescription prenatal vitamins as well as over-the-counter vitamins and
cosmetics. The Company is currently focused on conducting the clinical trials
necessary for regulatory approval and commercialization of advanced hormone
therapy pharmaceutical products designed to alleviate the symptoms of and
reduce the health risks resulting from menopause-related hormone deficiencies.
Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding TherapeuticsMD’s
expectations with respect to the completion and timing of the proposed public
offering, are forward-looking statements within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and uncertainties that
may cause actual results to differ materially, including the risks and
uncertainties associated with market conditions, the satisfaction of customary
closing conditions related to the proposed public offering, risks and
uncertainties associated with TherapeuticsMD’s business and finances in
general, and other risks detailed in TherapeuticsMD’s annual report on Form
10-K filed with the SEC on March 12, 2013, and other filings with the SEC.
These forward-looking statements are based on current information that may
change and you are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. All forward-looking statements are qualified in their entirety by
this cautionary statement, and TherapeuticsMD undertakes no obligation to
revise or update any forward-looking statement to reflect events or
circumstances after the issuance of this press release.
Daniel A. Cartwright, 561-961-1911
Chief Financial Officer
In-Site Communications, Inc.
Lisa M. Wilson, 917-543-9932
Healthcare Investor Relations
Press spacebar to pause and continue. Press esc to stop.